PMV Pharmaceuticals(US:PMVP)2025-11-12 13:00Financial Performance - PMV Pharmaceuticals reported a net loss of $21.1 million for Q3 2025, compared to a net loss of $19.2 million in Q3 2024, primarily due to increased R&D costs[10] - Total operating expenses for Q3 2025 were $22.5 million, compared to $21.9 million in Q3 2024[17] - The company reported total comprehensive loss of $20.99 million for Q3 2025[17] - PMV Pharma's accumulated deficit increased to $428.4 million as of September 30, 2025, from $368.7 million at the end of 2024[15] Research and Development - R&D expenses for Q3 2025 were $18.2 million, up from $16.9 million in Q3 2024, driven by higher contractual research organization costs for the rezatapopt program[10] - The overall response rate (ORR) for the rezatapopt study was 34% among 103 evaluable patients, with a median duration of response of 7.6 months[4] - In the ovarian cancer cohort, the ORR was 46% among 48 evaluable patients, with a median duration of response of 8.0 months[4] - The median time to response across all cohorts in the rezatapopt study was 1.3 months[5] Future Plans - PMV Pharma plans to submit a New Drug Application (NDA) for rezatapopt in the first quarter of 2027 for the treatment of platinum-resistant/refractory ovarian cancer[4] Cash Position - The company ended Q3 2025 with $129.3 million in cash, cash equivalents, and marketable securities, down from $148.3 million as of June 30, 2025[7]